andamertinib

Andamertinib (PLB1004) is an oral, potent, irreversible, and highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It demonstrates strong blood-brain barrier penetration and broad tyrosine kinase activity. Andamertinib is designed to target both classical EGFR mutations (such as Del19, L858R, T790M) as well as exon 20 insertions with high selectivity. The drug is being developed primarily for the treatment of non-small cell lung cancer (NSCLC), particularly in patients who have developed resistance to prior EGFR-TKI therapy due to MET amplification or overexpression. Clinical studies have shown promising efficacy in this population, including those with brain metastases[5][10].

Other names

andamertinibPLB1004PLB-1004PLB 1004